Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

Today, Editas is the only one of the original three CRISPR companies without any medicines in clinical trials. Its first program, in a rare eye disease, failed in 2022 after extensive delays.

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).